SUBSTITUTED-PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS
申请人:——
公开号:US20020091147A1
公开(公告)日:2002-07-11
This invention relates to compounds which are generally IP receptor modulators, particularly IP receptor antagonists, and which are represented by Formula I:
1
wherein A, R
1
and R
2
are as defined in the specification; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.
SUBSTITUTED 2-PHENYLAMINOIMIDAZOLINE PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS
申请人:F. HOFFMANN-LA ROCHE AG
公开号:EP1339694A1
公开(公告)日:2003-09-03
US6417186B1
申请人:——
公开号:US6417186B1
公开(公告)日:2002-07-09
[EN] SUBSTITUTED 2-PHENYLAMINOIMIDAZOLINE PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS<br/>[FR] DERIVES DE 2-PHENYLAMINOIMIDAZOLINE PHENYLE CETONE SUBSTITUES UTILISES COMME ANTAGONISTES DE LA PROSTAGLANDINE I2
申请人:HOFFMANN LA ROCHE
公开号:WO2002040453A1
公开(公告)日:2002-05-23
This invention relates to compounds which are generally prostaglandins I2 (IP) receptor modulators, particularly IP receptor antagonists, and which are represented by the general formula (I) wherein A, R?1 and R2¿ are defined in the specification; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, a process for the preparation of such compounds and their use for treating diseases associated with pain, inflammation, urinary tract disease states, respiratory disease states, edema formation, or hypotensive vascular diseases.
Substituted-phenyl ketone derivatives as IP antagonists
申请人:Syntex (U.S.A.) LLC
公开号:US06417186B1
公开(公告)日:2002-07-09
This invention relates to compounds which are generally IP receptor modulators, particularly IP receptor antagonists, and which are represented by Formula I:
wherein A, R1 and R2 are as defined in the specification; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.